DMD Trial Testing Oral ASP0367 Recruiting Boys 8–16 in US

DMD Trial Testing Oral ASP0367 Recruiting Boys 8–16 in US

300053

DMD Trial Testing Oral ASP0367 Recruiting Boys 8–16 in US

A Phase 1b clinical trial evaluating Astellas Pharma’s ASP0367 is recruiting boys with Duchenne muscular dystrophy (DMD), ages 8–16, at six U.S. sites. The ongoing trial (NCT04184882) is evaluating the safety and tolerability of the investigational oral therapy, which is designed to improve muscle function in patients with DMD, the most common of the more than 30 types of muscular dystrophy. The study sites include the University of California Davis Health, the University of Kansas Medical Center,…

You must be logged in to read/download the full post.